<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.95095</article-id><article-id pub-id-type="publisher-id">ACM-30121</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190500000_33505521.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  食管癌中MARCH2和DLG1的表达及其临床意义
  Expression of MARCH2 and DLG1 in Esophagus Cancer and Their Clinical Significance
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夏</surname><given-names>丹</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>山东医学高等专科学校病理教研室，山东 临沂</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>05</month><year>2019</year></pub-date><volume>09</volume><issue>05</issue><fpage>631</fpage><lpage>637</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：检测食管癌组织中膜相关环指蛋白2 (MARCH2)和肿瘤抑制蛋白(DLG1)的蛋白表达水平并分析其与临床病理参数的关系及两者的相关性。方法：用免疫组织化学方法检测50例食管癌及20例正常食管组织中MARCH2和DLG1的蛋白表达水平。结果：MARCH2和DLG1在50例食管癌组织中的阳性表达率分别为84%和18%，而MARCH2和DLG1在非肿瘤肠组织中的阳性表达率分别为25%和85%。MARCH2的阳性表达与更大肿瘤直径、不良分化、深度浸润、淋巴结转移和更高的TNM分期密切相关。DLG1表达的缺失与不良分化、深度浸润、淋巴结转移和更高的TNM分期密切相关。而且，MARCH2和DLG1的表达呈显著负相关。结论：MARCH2的高表达和DLG1表达的缺失可能促进食管癌的发生发展，并且与低分化和预后不良有关。MARCH2拮抗DLG1以促进食管癌的侵袭和转移。
    Aims: This study aimed to investigate whether the expressions of MARCH2 and DLG1 in esophagus carcinomas were associated with clinicopathological parameters. Methods: The expressions of MARCH2 and DLG1 were examined in 50 cases of esophagus carcinomas and 20 normal esophagus tissues using immunohistochemical staining. Results: The positive rates of MARCH2 and DLG1 ex-pressions in 50 cases of esophagus carcinoma were 84% and 18% respectively, whereas the posi-tive expression rates of MARCH2 and DLG1 in non-tumor intestinal tissues were 25% and 85% respectively. The positive expressions of MARCH2 were closely related to larger tumor, poor dif-ferentiation, deeper invasion, lymphnode metastasis and advanced TNM stage. In addition, loss of expression of DLG1 was significantly associated with poor differentiation, deeper invasion, lymphnode metastasis and advanced TNM stage. Furthermore, there were significant negative correlations between MARCH2 and DLG1 expression. Conclusions: The overexpression of MARCH2 and loss of expression of DLG1 were possibly involved in the development of esophagus carcinomas, and had correlations with low differentiation degree and bad prognosis. MARCH2 antagonized DLG1 to promote invasion and metastasis of esophagus cancer. 
  
 
</p></abstract><kwd-group><kwd>食管肿瘤，MARCH2，DLG1，免疫组织化学, Esophagus Cancer</kwd><kwd> MARCH2</kwd><kwd> DLG1</kwd><kwd> Immunohistochemistry</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>食管癌中MARCH2和DLG1的表达 及其临床意义<sup> </sup></title><p>夏丹</p><p>山东医学高等专科学校病理教研室，山东 临沂</p><p><img src="//html.hanspub.org/file/1-1570845x1_hanspub.png" /></p><p>收稿日期：2019年4月16日；录用日期：2019年5月2日；发布日期：2019年5月9日</p><disp-formula id="hanspub.30121-formula1"><graphic xlink:href="//html.hanspub.org/file/1-1570845x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：检测食管癌组织中膜相关环指蛋白2 (MARCH2)和肿瘤抑制蛋白(DLG1)的蛋白表达水平并分析其与临床病理参数的关系及两者的相关性。方法：用免疫组织化学方法检测50例食管癌及20例正常食管组织中MARCH2和DLG1的蛋白表达水平。结果：MARCH2和DLG1在50例食管癌组织中的阳性表达率分别为84%和18%，而MARCH2和DLG1在非肿瘤肠组织中的阳性表达率分别为25%和85%。MARCH2的阳性表达与更大肿瘤直径、不良分化、深度浸润、淋巴结转移和更高的TNM分期密切相关。DLG1表达的缺失与不良分化、深度浸润、淋巴结转移和更高的TNM分期密切相关。而且，MARCH2和DLG1的表达呈显著负相关。结论：MARCH2的高表达和DLG1表达的缺失可能促进食管癌的发生发展，并且与低分化和预后不良有关。MARCH2拮抗DLG1以促进食管癌的侵袭和转移。</p><p>关键词 :食管肿瘤，MARCH2，DLG1，免疫组织化学</p><disp-formula id="hanspub.30121-formula2"><graphic xlink:href="//html.hanspub.org/file/1-1570845x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1570845x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-1570845x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>食管癌是最具侵袭性的癌症之一，是世界范围内癌症致死的第六大原因。全球大约70%的食管癌发生在中国。目前，食管癌的早期诊断和治疗方法有限，导致患者五年生存率只有10% [<xref ref-type="bibr" rid="hanspub.30121-ref1">1</xref>] 。</p><p>MARCH2 (Membrane-associated RING-CH protein 2)是MARCH家族成员之一(MARCH1-11)，含有RING结构域、两个跨膜区和PDZ结构域 [<xref ref-type="bibr" rid="hanspub.30121-ref2">2</xref>] 。MARCH2最初被认为是与病毒免疫逃逸蛋白相关的泛素连接酶家族成员之一 [<xref ref-type="bibr" rid="hanspub.30121-ref2">2</xref>] 。功能性研究显示MARCH2能减低细胞表面受体如转铁蛋白受体和共刺激分子B7.2 [<xref ref-type="bibr" rid="hanspub.30121-ref2">2</xref>] 。Nakamura研究团队发现MARCH2可以直接特异性结合STX6，参与内体到高尔基体的运输 [<xref ref-type="bibr" rid="hanspub.30121-ref3">3</xref>] 。Guggino的研究显示MARCH2可以结合CAL和STX6，促进CFTR的泛素化和降解 [<xref ref-type="bibr" rid="hanspub.30121-ref4">4</xref>] 。Shenoy报道MARCH2与β2AR相互结合可以促进β2AR的泛素化，调节β2AR在细胞表面的水平 [<xref ref-type="bibr" rid="hanspub.30121-ref5">5</xref>] 。近来，Xavier课题组证实MARCH2通过PDZ膜序与DLG1相互作用，促进DLG1泛素化并减低DLG1在细胞链接处的表达水平，干扰细胞的极性 [<xref ref-type="bibr" rid="hanspub.30121-ref6">6</xref>] 。另有报道称DLG1在人类肿瘤中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.30121-ref7">7</xref>] 。</p><p>DLG1 (Human Discs large tumour suppressor)是膜相关的鸟苷酸激酶家族一员，包含多个PDZ结构域(PSD, DLG1, ZO-1)，每个PDZ由90个氨基酸左右组成，能够通过特异性识别配体蛋白C末端的氨基酸残基介导蛋白质之间的相互作用，属于分子脚手架蛋白。DLG1是Scribble极性复合体的一个组成部分，参与调节细胞极性和增殖，在上皮组织和细胞生长调控之间发挥重要的连接作用 [<xref ref-type="bibr" rid="hanspub.30121-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.30121-ref9">9</xref>] 。有文献报道，在几种不同类型肿瘤中，DLG1的表达缺失与恶性进展的晚期时细胞极性和组织架构的完全缺失密切相关，因此定义DLG1为潜在的肿瘤抑制因子 [<xref ref-type="bibr" rid="hanspub.30121-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.30121-ref11">11</xref>] 。此外，DLG1在人类发挥肿瘤抑制活性的最令人信服的依据是DLG1被鉴定为几种病毒癌基因蛋白的靶标，如人乳头状瘤病毒(HPV) E6，人T细胞白血病病毒类型1Tax和腺病毒类型9 E4-ORF1 [<xref ref-type="bibr" rid="hanspub.30121-ref12">12</xref>] 。然而，近来的研究显示DLG1在一些特异的环境中可以获得癌基因属性，DLG1表达减低在人类肿瘤生成中发挥重要的作用 [<xref ref-type="bibr" rid="hanspub.30121-ref9">9</xref>] 。</p><p>在本研究中，我们应用免疫组织化学染色的方法检测了50例食管癌组织中MARCH2和DLG1的表达情况，并对MARCH2和DLG1表达之间相关性以及二者与临床病理参数之间的相关性进行了分析。</p></sec><sec id="s4"><title>2. 材料和方法</title><sec id="s4_1"><title>2.1. 临床食管癌标本</title><p>回顾性分析2004年3月~2014年10月在山东医学高等专科学校附属医院进行手术治疗的50例食管癌患者的临床资料，选取癌旁正常食管组织20例作为对照。所有患者均经2名病理医师确诊为食管癌。所选病例临床资料完整。该研究已获得相应的伦理许可。</p></sec><sec id="s4_2"><title>2.2. 试剂及抗体</title><p>多克隆兔抗人MARCH2抗体购自美国Abcam公司；多克隆兔抗人DLG1抗体购自美国Abclonal公司，免疫组织化学染色试剂盒购自北京中杉金桥公司。</p></sec><sec id="s4_3"><title>2.3. 检测方法</title><p>应用免疫组化SP法进行指标检测。所有采集的标本均制成蜡块，连续切片，厚4μm，脱蜡、水化，3%过氧化氢甲醇溶液去除内源性过氧化物酶，PBS缓冲液冲洗，EDTA (pH = 9.0)高压热修复，滴入1:100稀释的一抗MARCH2或1:100稀释的一抗DLG1，4℃过夜，滴入二抗，室温1小时，DAB显色。用已知MARCH2和DLG1阳性切片作阳性对照，以PBS代替一抗作阴性对照。</p></sec><sec id="s4_4"><title>2.4. 结果评估</title><p>每张切片随机选取有代表意义的5个高倍视野，每高倍视野需计数200个细胞，应用IRS免疫反应评分(immunoreactivity score) [<xref ref-type="bibr" rid="hanspub.30121-ref13">13</xref>] ，把着色细胞数的比例和着色的强度结合起来。① 按着色细胞占计数细胞百分比计分：0分(阴性)，1分(&lt;10%)，2分(11%~50%)，3分(51%~80%)，4分(&gt;80%)。② 按着色的强度计分：0分(无着色)，1分(淡黄色)，2分(黄色)，3分(棕黄色)。总分 = ① &#215; ②：0分(阴性，−)；1~3分(弱阳性，+)；4~7分(中等阳性，++)；8~12分(强阳性，+++)。</p></sec><sec id="s4_5"><title>2.5. 统计学分析</title><p>应用SPSS 20.0软件进行统计学分析，组间比较采用χ<sup>2</sup>检验，两变量间的相关性采用Spearman等级相关性分析，P &lt; 0.05的差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. MARCH2和DLG1的检测结果</title><p>MARCH2呈弥漫的棕色细颗粒状表达，染色主要位于肿瘤细胞的细胞质，部分位于细胞核(图1 A)。MARCH2在50例食管癌组织中，呈现阴性表达的有8例，呈现弱阳性表达的有9例，呈现中度阳性表达的有21例，呈现强阳性表达的有12例。MARCH2在食管癌组织中的阳性表达率为84% (42/50)。在20例非肿瘤食管组织中，有15例呈现阴性表达，5例呈现弱阳性表达。MARCH2在非肿瘤食管组织中阳性表达率为25% (5/20)。MARCH2在食管癌组织中的阳性表达率84% (42/50)明显高于非肿瘤食管组织6.7% (2/30)，其差异有统计学意义(P &lt; 0.01，表1，图1 A)。</p><p>DLG1染色主要位于肿瘤细胞的细胞质和(或)细胞膜(图1 B)。在50例食管癌组织中，DLG1的阳性表达率为18% (9/50)。在20例非肿瘤食管组织中，有3例为阴性表达，3例为弱阳性表达，10例呈现中度阳性表达，4例呈现强阳性表达。DLG1在非肿瘤食管组织中阳性表达率为85.0% (17/20)。DLG1在食管癌组织中的阳性表达率18% (9/50)明显低于非肿瘤食管组织85% (17/20)，差异具有统计学意义(P &lt; 0.01，表1，图1 B)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Expression of MARCH2 and DLG1 in esophagus carcinomas and non-tumor esophagus tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >免疫染色</th><th align="center" valign="middle"  colspan="2"  >标本类型</th></tr></thead><tr><td align="center" valign="middle" >MARCH2</td><td align="center" valign="middle" >非肿瘤食管组织</td><td align="center" valign="middle" >食管癌组织</td></tr><tr><td align="center" valign="middle" >－</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >＋＋</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle" >＋＋＋</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >标本总数</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >阳性率(%)</td><td align="center" valign="middle" >25.0%</td><td align="center" valign="middle" >84.0%</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >DLG1</td><td align="center" valign="middle" >非肿瘤食管组织</td><td align="center" valign="middle" >食管癌组织</td></tr><tr><td align="center" valign="middle" >－</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >41</td></tr><tr><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >＋＋</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >＋＋＋</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >标本总数</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >阳性率(%)</td><td align="center" valign="middle" >85.0%</td><td align="center" valign="middle" >18.0%</td></tr></tbody></table></table-wrap><p>表1. MARCH2和DLG1在食管癌及非肿瘤食管组织中的表达</p><p>图1. MARCH2和DLG1在食管癌组织中的免疫组织化学染色；(A) MARCH2在食管癌组织中的阳性表达(SP, &#215;400)；(B) DLG1在食管癌组织中的阳性表达(SP, &#215;400)</p></sec><sec id="s5_2"><title>3.2. MARCH2和DLG1的表达与患者临床病理特征的关系</title><p>根据免疫组织化学染色的IRS评分，我们分析了MARCH2和DLG1表达与食管癌患者的临床病理特征的关系。如表2所示，MARCH2的阳性表达与食管癌更大的肿瘤直径(P &lt; 0.05)、更差的分化程度(P &lt; 0.01)、更深的浸润深度(P &lt; 0.01)、淋巴结转移(P &lt; 0.05)和更高的TNM分期密切相关(P &lt; 0.01)。MARCH2的阳性表达与年龄和性别没有明显的相关性。DLG1的阳性表达与食管癌患者的更差的分化程度(P &lt; 0.05)、更深的浸润深度(P &lt; 0.05)、淋巴结转移(P &lt; 0.01)和更高的TNM分期(P &lt; 0.01)密切相关。DLG1的阳性表达与性别、年龄和肿瘤大小没有明显的相关性。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Association of MARCH2 and DLG1 staining with clinicopathological characteristic</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床病理特征</th><th align="center" valign="middle"  colspan="2"  >MARCH2</th><th align="center" valign="middle"  rowspan="2"  >χ<sup>2</sup></th><th align="center" valign="middle"  rowspan="2"  >P值</th><th align="center" valign="middle"  colspan="2"  >DLG1</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+~+++</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+~+++</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >0.42</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0.06</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0.06</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.28</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤直径(cm)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤5 cm</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >5.36</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.36</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >&gt;5 cm</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高+中</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >14.88</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >5.28</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >低</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浸润深度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1 + T2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >7.19</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.55</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >T3 + T4</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >4.35</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >13.0</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TNM stage</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I + II</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6.21</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >14.9</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >III + IV</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. MARCH2和DLG1表达与食管癌临床病理特征的关系</p></sec><sec id="s5_3"><title>3.3. MARCH2和DLG1之间的相关性</title><p>如表3所示，MARCH2表达与DLG1表达呈现显著的负相关(P &lt; 0.001)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between MARCH2 and DLG1 in esophagus cancer tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  rowspan="2"  >病例数</th><th align="center" valign="middle"  colspan="2"  >MARCH2表达</th></tr></thead><tr><td align="center" valign="middle" >+</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >DLG1表达</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >39 (95.1%)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >+</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3 (33.3%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 食管癌组织中MARCH2和DLG1之间的相关性</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>MARCH2是由N端RING结构域、跨膜区以及C端的PDZ结构域组成的二次跨膜蛋白 [<xref ref-type="bibr" rid="hanspub.30121-ref2">2</xref>] 。Xavier科研团队证实MARCH2能够定位于HEK293T细胞的细胞膜 [<xref ref-type="bibr" rid="hanspub.30121-ref6">6</xref>] 。作为E3泛素连接酶，MARCH2在细胞的连接处促进DLG1的泛素化和降解，干扰细胞极性。已有研究表明DLG1在人类肿瘤中发挥着非常重要的作用 [<xref ref-type="bibr" rid="hanspub.30121-ref7">7</xref>] ，而MARCH2在肿瘤中的作用却鲜有报道。Suqihara [<xref ref-type="bibr" rid="hanspub.30121-ref13">13</xref>] 研究小组报道细胞极性决定因素DLG1的缺失是子宫内膜癌淋巴结转移和不良预后的新分子标志物。DLG1位于正常子宫内膜组织的细胞膜。DLG1缺失常出现在较晚临床分期、高级别组织学分级、淋巴结转移、深部子宫肌层浸润和阴性雌激素/孕激素受体的患者。DLG1缺失的患者总生存率较低。体外实验表明在子宫内膜癌细胞中敲减DLG1导致肿瘤迁移和侵袭加速 [<xref ref-type="bibr" rid="hanspub.30121-ref11">11</xref>] 。Daniela [<xref ref-type="bibr" rid="hanspub.30121-ref14">14</xref>] 课题组报道DLG1极性蛋白表达与低级别宫颈上皮内瘤变的疾病进展相关。他们的数据表明DLG1染色样式与正常组织相似的低度病变患者更有可能倒退(n = 23, Pattern I)，所有的弥漫的强DLG1染色的低度病变标本可能向高级别病变进展(n = 4, Pattern II)。最后，所有持久稳固的低度病变的分析显示未确定的DLG1染色(弥漫分布且无高强度的染色) (n = 3, Pattern III)。他们发现DLG1表达样式和病变的进展呈显著相关性。因而，我们提出一个假设，MARCH2有可能是通过DLG1来参与肿瘤的发生及进展。</p><p>在本研究中，我们用免疫组织化学染色的方法检测了食管癌组织中MARCH2和DLG1的表达情况，并且分析了二者之间的相关性以及与临床病理特征的相关性。我们发现MARCH2在食管癌组织中的表达比在非肿瘤食管组织显著升高，提示MARCH2可能参与了肿瘤的发生。尤其是，我们的结果显示MARCH2的阳性染色更多出现在肿瘤直径更大、不良分化、浸润更深、有淋巴结转移和更高TNM分期的肿瘤，提示MARCH2可能在肿瘤的进展中发挥作用。相反，食管癌组织中DLG1的表达比在非肿瘤食管组织中有明显降低，而且DLG1的表达缺失与不良分化、浸润更深、淋巴结转移和更高的TNM分期密切相关。此外，MARCH2表达与DLG1呈负性相关。这些结果提示MARCH2过表达和DLG1低表达参与了食管癌的发生及进展。MARCH2和DLG1的联合检测可能为食管癌的诊断、治疗和预后提供依据。</p></sec><sec id="s7"><title>基金项目</title><p>本研究由国家自然科学基金项目(81702776)；山东省高等学校科技计划项目(J17KA238)；山东省医药卫生科技发展计划项目(2016WS0569)资助。</p></sec><sec id="s8"><title>文章引用</title><p>夏 丹. 食管癌中MARCH2和DLG1的表达及其临床意义Expression of MARCH2 and DLG1 in Esophagus Cancer and Their Clinical Significance[J]. 临床医学进展, 2019, 09(05): 631-637. https://doi.org/10.12677/ACM.2019.95095</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30121-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Song, Y., et al. (2014) Identification of Genomic Alterations in Oesophageal Squamous Cell Cancer. Nature, 509, 91-95. &lt;br&gt;https://doi.org/10.1038/nature13176</mixed-citation></ref><ref id="hanspub.30121-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bartee, E., Mansouri, M., Hovey, N.B., Gouveia, K. and Fruh, K. (2004) Downregulation of Major Histocompatibility Complex Class I by Human Ubiquitin Ligases Related to Viral Immune Evasion Proteins. Journal of Virology, 78, 1109-1120. &lt;br&gt;https://doi.org/10.1128/JVI.78.3.1109-1120.2004</mixed-citation></ref><ref id="hanspub.30121-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, N., Fukuda, H., Kato, A. and Hirose, S. (2005) MARCH-II Is a Syntaxin-6-Binding Protein Involved in Endosomal Trafficking. Molecular Biology of the Cell, 16, 1696-1710. &lt;br&gt;https://doi.org/10.1091/mbc.e04-03-0216</mixed-citation></ref><ref id="hanspub.30121-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, J. and Guggino, W. (2013) Ubiquitination and Degradation of CFTR by the E3 Ubiquitin Ligase MARCH2 through Its Association with Adaptor Proteins CAL and STX6. PLoS ONE, 8, e68001.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0068001</mixed-citation></ref><ref id="hanspub.30121-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Han, S.O., et al. (2012) MARCH2 Promotes Endocytosis and Lysosomal Sorting of Carvedilol-Bound Beta(2)-Adrenergic Receptors. The Journal of Cell Biology, 199, 817-830. &lt;br&gt;https://doi.org/10.1083/jcb.201208192</mixed-citation></ref><ref id="hanspub.30121-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cao, Z., Huett, A., Kuballa, P., Giallourakis, C. and Xavier, R.J. (2008) DLG1 Is an Anchor for the E3 Ligase MARCH2 at Sites of Cell-Cell Contact. Cell Signal, 20, 73-82. &lt;br&gt;https://doi.org/10.1016/j.cellsig.2007.08.019</mixed-citation></ref><ref id="hanspub.30121-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sandoval, G.J., et al. (2013) Novel Mechanism of Tumor Sup-pression by Polarity Gene Discs Large 1 (DLG1) Revealed in a Murine Model of Pediatric B-ALL. Cancer Immunology Research, 1, 426-437.  
&lt;br&gt;https://doi.org/10.1158/2326-6066.CIR-13-0065</mixed-citation></ref><ref id="hanspub.30121-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Assemat, E., Bazellieres, E., Pallesi-Pocachard, E., Le Bivic, A. and Massey-Harroche, D. (2008) Polarity Complex Proteins. Biochimica et Biophysica Acta, 1778, 614-630. &lt;br&gt;https://doi.org/10.1016/j.bbamem.2007.08.029</mixed-citation></ref><ref id="hanspub.30121-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, S., Delury, C. and Marsh, E. (2012) The PDZ Protein Discs-Large (DLG): The “Jekyll and Hyde” of the Epithelial Polarity Proteins. The FEBS Journal, 279, 3549-3558. &lt;br&gt;https://doi.org/10.1111/j.1742-4658.2012.08729.x</mixed-citation></ref><ref id="hanspub.30121-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Facciuto, F., Cavatorta, A.L., Valdano, M.B., Marziali, F. and Gardiol, D. (2012) Differential Expression of PDZ Domain-Containing Proteins in Human Diseases-Challenging Topics and Novel Issues. The FEBS Journal, 279, 3538-3548. &lt;br&gt;https://doi.org/10.1111/j.1742-4658.2012.08699.x</mixed-citation></ref><ref id="hanspub.30121-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sugihara, T., et al. (2016) Loss of the Cell Polarity De-terminant Human Discs-Large Is a Novel Molecular Marker of Nodal Involvement and Poor Prognosis in Endometrial Cancer. British Journal of Cancer, 114, 1012-1018.  
&lt;br&gt;https://doi.org/10.1038/bjc.2016.24</mixed-citation></ref><ref id="hanspub.30121-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">James, C.D. and Roberts, S. (2016) Viral Interactions with PDZ Do-main-Containing Proteins—An Oncogenic Trait? Pathogens, 5, pii: E8. &lt;br&gt;https://doi.org/10.3390/pathogens5010008</mixed-citation></ref><ref id="hanspub.30121-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Metindir, J., et al. (2008) Staining Characterization by Immuno-histochemistry of Tumor Cancer Antigen in Patients with Endometrial Cancer. European Journal of Gynaecological Oncology, 29, 489-492.</mixed-citation></ref><ref id="hanspub.30121-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cavatorta, A.L., et al. (2017) DLG1 Polarity Protein Expression Associates with the Disease Progress of Low-Grade Cervical Intraepithelial Lesions. Experimental and Molecular Pathology, 102, 65-69.  
&lt;br&gt;https://doi.org/10.1016/j.yexmp.2016.12.008</mixed-citation></ref></ref-list></back></article>